GSK initiate Phase I trial of Muscarinic M1 antagonist GSK1034702

Posted on September 2, 2008 by crimsoncanary

GSK have initiated a Phase I trial of Muscarinic M1 antagonist GSK1034702

Filed under: gpcr | Tagged: , , , , , | Leave a comment »

Mithridion commences Phase I Trial of MCD-386 for Alzheimer’s Disease

Posted on July 14, 2008 by crimsoncanary

Mithridion has commenced a Phase I clinical trial of its investigational drug MCD-386 in Alzheimers. MCD-386 appears to activate of muscarinic M1 type receptor subtypes.

Filed under: Uncategorized | Tagged: , , , , , , | Leave a comment »

Lillys long acting injection olanzapine shows similar profile to Zyprexa

Posted on June 23, 2008 by crimsoncanary

Data prsented at the Schizophrenia International Research Society meeting show Lilly’s long acting injection (LAI) formulation of olanzapine to demonstrate similar efficacy and safety to Zyprexa.

Filed under: gpcr | Tagged: , , , , , , , , , , , , , , , , , , | Leave a comment »

Acadias ACP-104 does not meet endpoint in Phase IIb Schizophrenia trial

Posted on June 16, 2008 by crimsoncanary

Acadia’s ACP-104 did not meet its primary endpoint of antipsychotic efficacy in a Phase IIb Schizophrenia trial

Filed under: gpcr | Tagged: , , , , , , , , , , , | Leave a comment »